MA35110B1 - Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae - Google Patents

Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae

Info

Publication number
MA35110B1
MA35110B1 MA36409A MA36409A MA35110B1 MA 35110 B1 MA35110 B1 MA 35110B1 MA 36409 A MA36409 A MA 36409A MA 36409 A MA36409 A MA 36409A MA 35110 B1 MA35110 B1 MA 35110B1
Authority
MA
Morocco
Prior art keywords
pilin
fusion proteins
haemophilus influenzae
polyvaccines
including protein
Prior art date
Application number
MA36409A
Other languages
English (en)
Inventor
Normand Blais
Steve Labbe
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47008755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35110(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA35110B1 publication Critical patent/MA35110B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositions comprenant la protéine e et la piline a d'haemophilus influenzae. Plus particulièrement, la présente demande concerne des protéines de fusion et des compositions immunogènes comprenant la protéine e et pila, des vaccins contenant ces compositions immunogènes et leurs utilisations thérapeutiques.
MA36409A 2011-04-13 2013-11-08 Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae MA35110B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474779P 2011-04-13 2011-04-13
US201161534012P 2011-09-13 2011-09-13
PCT/CA2012/050236 WO2012139225A1 (fr) 2011-04-13 2012-04-12 Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae

Publications (1)

Publication Number Publication Date
MA35110B1 true MA35110B1 (fr) 2014-05-02

Family

ID=47008755

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36409A MA35110B1 (fr) 2011-04-13 2013-11-08 Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae

Country Status (36)

Country Link
US (7) US8945577B2 (fr)
EP (2) EP3321287B1 (fr)
JP (1) JP6196963B2 (fr)
KR (1) KR101999673B1 (fr)
CN (3) CN107383201A (fr)
AR (1) AR086078A1 (fr)
AU (1) AU2012243412C1 (fr)
BR (1) BR112013026175B1 (fr)
CA (1) CA2830786C (fr)
CL (1) CL2013002937A1 (fr)
CO (1) CO6781540A2 (fr)
CR (1) CR20130529A (fr)
CY (2) CY1120319T1 (fr)
DK (2) DK3321287T3 (fr)
DO (1) DOP2013000235A (fr)
EA (1) EA031580B1 (fr)
ES (2) ES2658512T3 (fr)
HR (2) HRP20180216T1 (fr)
HU (2) HUE048848T2 (fr)
IL (2) IL271862B (fr)
LT (2) LT3321287T (fr)
MA (1) MA35110B1 (fr)
ME (1) ME02995B (fr)
MX (1) MX350013B (fr)
PE (1) PE20140986A1 (fr)
PH (1) PH12013502121A1 (fr)
PL (2) PL3321287T3 (fr)
PT (2) PT2707393T (fr)
RS (1) RS56903B1 (fr)
SG (2) SG10201602549WA (fr)
SI (2) SI2707393T1 (fr)
SM (1) SMT201800125T1 (fr)
TW (1) TW201302779A (fr)
UY (1) UY34017A (fr)
WO (1) WO2012139225A1 (fr)
ZA (1) ZA201307118B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
JP6236086B2 (ja) * 2012-10-17 2017-11-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CA3209225A1 (fr) 2013-09-30 2015-04-02 Island Abbey Foods Limited Produit a macher et son procede de production
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
CN107532204A (zh) * 2015-01-16 2018-01-02 肯塔基大学研究基金会 脂质双层集成spp1连接子蛋白纳米孔和作为脂质双层集成纳米孔的spp1连接子蛋白变体
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3057778A1 (fr) * 2017-03-31 2018-10-04 Glaxosmithkline Biologicals Sa Composition immunogene, utilisation et methode de traitement
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
CA3072018A1 (fr) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Procedes d'amplification des reponses immunitaires
CN107602697B (zh) * 2017-08-29 2020-05-05 杭州医学院 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
BR112020024514A2 (pt) * 2018-06-19 2021-03-02 Glaxosmithkline Biologicals S.A. composição imunogênica
EP3833382A1 (fr) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processus et vaccins
WO2020109365A1 (fr) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
CN110540598B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
US20220143168A1 (en) 2019-02-27 2022-05-12 Evaxion Biotech A/S Vaccines targeting H. influenzae
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
EP4010014A1 (fr) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP4294433A1 (fr) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Composition immunogène, utilisation et procédés
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
EP4558170A1 (fr) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Procédé continu de production de vaccin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5601831A (en) 1989-03-09 1997-02-11 Praxis Biologics, Inc. Vaccines for nontypable Haemophilus influenzae
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (fr) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
IL122588A (en) 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
ATE497004T1 (de) 1996-12-20 2011-02-15 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
SI2270171T1 (sl) 2000-10-02 2013-12-31 Id Biomedical Corporation Of Quebec Antigeni Haemophilusa influenzae in ustrezni fragmenti DNA
WO2002083710A2 (fr) 2001-04-13 2002-10-24 Wyeth Holdings Corporation Elimination d'endotoxine bacterienne dans une solution proteique par chromatographie d'affinite metallique immobilisee
WO2003035836A2 (fr) 2001-10-24 2003-05-01 Hybridon Inc. Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
CA2531698A1 (fr) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Methode de detection d'une interaction proteine-proteine
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
PE20061441A1 (es) * 2005-05-12 2007-01-18 Novartis Ag Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
RU2412249C2 (ru) * 2005-07-08 2011-02-20 Юниверсити Оф Цюрих Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов
CA2613970C (fr) * 2005-07-08 2015-12-08 Children's Hospital, Inc. Vaccin chimere pour maladie provoquee par haemophilus influenzae
US8092811B2 (en) 2005-08-10 2012-01-10 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
SG10201600336RA (en) 2006-01-17 2016-02-26 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
GB2444903A (en) * 2006-12-21 2008-06-25 Secr Defence Live Francisella vaccine, inactivated at gene FTT1564
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Also Published As

Publication number Publication date
WO2012139225A1 (fr) 2012-10-18
ES2658512T3 (es) 2018-03-12
US20200331972A1 (en) 2020-10-22
PL3321287T3 (pl) 2020-07-27
EP2707393A1 (fr) 2014-03-19
SG10201602549WA (en) 2016-05-30
SMT201800125T1 (it) 2018-05-02
CA2830786A1 (fr) 2012-10-18
ME02995B (fr) 2018-10-20
US20180222946A1 (en) 2018-08-09
SI2707393T1 (en) 2018-03-30
EP2707393A4 (fr) 2014-11-05
RS56903B1 (sr) 2018-05-31
KR20140026483A (ko) 2014-03-05
SI3321287T1 (sl) 2020-07-31
DK3321287T3 (da) 2020-05-04
MX2013011939A (es) 2014-03-27
UY34017A (es) 2012-11-30
US20150175670A1 (en) 2015-06-25
PH12013502121A1 (en) 2014-01-13
PE20140986A1 (es) 2014-08-20
EA031580B1 (ru) 2019-01-31
US10023616B2 (en) 2018-07-17
DOP2013000235A (es) 2014-03-16
LT2707393T (lt) 2018-03-12
US20140056934A1 (en) 2014-02-27
IL228344B (en) 2020-01-30
US20150166613A1 (en) 2015-06-18
PT2707393T (pt) 2018-02-09
US8945577B2 (en) 2015-02-03
PT3321287T (pt) 2020-05-22
MX350013B (es) 2017-08-23
CR20130529A (es) 2014-03-05
HUE048848T2 (hu) 2020-08-28
LT3321287T (lt) 2020-06-10
US10214569B2 (en) 2019-02-26
HRP20200466T1 (hr) 2020-06-26
US11198707B2 (en) 2021-12-14
IL271862A (en) 2020-02-27
SG193906A1 (en) 2013-11-29
CA2830786C (fr) 2021-10-26
EA201391240A1 (ru) 2014-04-30
ZA201307118B (en) 2022-03-30
US9409957B2 (en) 2016-08-09
AR086078A1 (es) 2013-11-20
JP6196963B2 (ja) 2017-09-13
KR101999673B1 (ko) 2019-07-12
US20160250313A1 (en) 2016-09-01
CL2013002937A1 (es) 2014-07-25
CN103476799A (zh) 2013-12-25
EP3321287A1 (fr) 2018-05-16
JP2014512365A (ja) 2014-05-22
US10730917B2 (en) 2020-08-04
CN107522788A (zh) 2017-12-29
IL228344A0 (en) 2013-12-31
US20170029472A1 (en) 2017-02-02
PL2707393T3 (pl) 2018-05-30
CY1122824T1 (el) 2021-05-05
ES2776369T3 (es) 2020-07-30
CO6781540A2 (es) 2013-10-31
DK2707393T3 (da) 2018-01-29
EP3321287B1 (fr) 2020-02-26
US9296794B2 (en) 2016-03-29
AU2012243412B2 (en) 2015-05-14
AU2012243412C1 (en) 2015-12-10
HRP20180216T1 (hr) 2018-03-09
CY1120319T1 (el) 2019-07-10
BR112013026175B1 (pt) 2020-05-12
AU2012243412A1 (en) 2013-04-18
EP2707393B1 (fr) 2017-12-20
IL271862B (en) 2022-07-01
TW201302779A (zh) 2013-01-16
HUE036983T2 (hu) 2018-08-28
BR112013026175A2 (pt) 2016-11-29
CN107383201A (zh) 2017-11-24
NZ615328A (en) 2015-10-30

Similar Documents

Publication Publication Date Title
MA35110B1 (fr) Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
IN2012DN02736A (fr)
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1118601T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
UA104005C2 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX360448B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
MY167723A (en) Neisseria meningitidis compositions and methods thereof
EA201590490A1 (ru) ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОДИН ИЛИ БОЛЕЕ КОНЪЮГАТОВ КАПСУЛЬНЫХ САХАРИДОВ STREPTOCOCCUS PNEUMONIAE И БЕЛКОВЫЙ КОМПОНЕНТ, ВКЛЮЧАЮЩИЙ БЕЛОК Е И/ИЛИ PilA ИЗ HAEMOPHILIUS INFLUENZAE
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
PH12013500143A1 (en) A method of treating alzheimer`s disease
EA201400827A1 (ru) Материалы и способы лечения диареи
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
EA201590752A1 (ru) Препараты производных пиримидиндиона
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EP2566508A4 (fr) Conjugaison de polysaccharide à une entérotoxine thermolabile (lt) d'e.coli détoxifiée, utilisée comme vaccin
MX2015009141A (es) Formulaciones de albu-bche, preparacion y usos de las mismas.